NCT02602249 is a Phase 1 clinical trial of MUC1-gene-DC-CTL in Gastric Cancer, sponsored by Beijing Doing Biomedical Co., Ltd..

Who is sponsoring NCT02602249?

NCT02602249 is sponsored by Beijing Doing Biomedical Co., Ltd..

What drugs are being tested in NCT02602249?

Interventions in NCT02602249: MUC1-gene-DC-CTL, MUC1-peptide-DC-CTL.

What condition does NCT02602249 study?

NCT02602249 studies Gastric Cancer.

Is NCT02602249 still recruiting?

NCT02602249 is currently status unknown. Last updated 1 September 2017.

Last reviewed 2017-09-01 · How we verify

NCT02602249

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1 Study of Antigen-specific Cytotoxic T Lymphocytes Induced by Dendritic Cells Infected by Recombinant Adeno-associated Virus With MUC1 Gene(MUC1-gene-DC-CTL) or Directly Pulsed by MUC1 Peptide(MUC1-peptide-DC-CTL) in Gastric Cancer.

Status unknown Phase 1 Last updated 1 September 2017

What this trial tests

Phase 1 trial testing MUC1-gene-DC-CTL in Gastric Cancer in 24 participants. Status unknown.

Timeline

1 October 2017

Primary endpoint
1 April 2019

1 April 2020

Quick facts

Lead sponsor	Beijing Doing Biomedical Co., Ltd.
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	1 October 2017
Primary completion	1 April 2019
Estimated completion	1 April 2020
Sites	3 locations across China

Drugs / interventions tested

MUC1-gene-DC-CTL — full drug profile →
MUC1-peptide-DC-CTL — full drug profile →

Conditions studied

Gastric Cancer — all drugs for Gastric Cancer →

Sponsor

Beijing Doing Biomedical Co., Ltd. — full company profile →

Who can join

Adults 18 to 80, any sex, with Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Reduced size of the tumor.
Time frame: up to one year
Tumor load will be evaluated by RECIST criteria.

Sponsor's own description

In this study, safety and effects of MUC1-gene-DC-CTL and MUC1-peptide-DC-CTL on human gastric cancer are going to be investigated.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Adeno-associated virus (AAV) vectors in cancer gene therapy.
Santiago-Ortiz JL, Schaffer DV. · · 2016 · cited 175× · PMID 26796040 · DOI 10.1016/j.jconrel.2016.01.001
Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets.
Kumar AR, Devan AR, Nair B, Vinod BS, et al · · 2021 · cited 98× · PMID 34671902 · DOI 10.1007/s11033-021-06752-9
Trial watch: Dendritic cell-based anticancer immunotherapy.
Garg AD, Vara Perez M, Schaaf M, Agostinis P, et al · · 2017 · cited 82× · PMID 28811970 · DOI 10.1080/2162402x.2017.1328341
Adeno-associated virus (AAV)-based gene therapy for glioblastoma.
Xu X, Chen W, Zhu W, Chen J, et al · · 2021 · cited 27× · PMID 33499886 · DOI 10.1186/s12935-021-01776-4
Advances in Human Dendritic Cell-Based Immunotherapy Against Gastrointestinal Cancer.
Ni L. · · 2022 · cited 16× · PMID 35619702 · DOI 10.3389/fimmu.2022.887189
ZNF146 accelerates lung adenocarcinoma progression through MDM2/p53 and PHGDH/ferroptosis.
Zhu J, Ren S, Yi Y, Wu Z, et al · · 2025 · cited 2× · PMID 40581637 · DOI 10.1186/s13578-025-01433-7
Application of dendritic cell extracellular vesicles as a valid nanoparticle platform for cancer therapies: a narrative review.
Nezamdoust FV, Nezhad-Mokhtari P, Mirzaahmadi B, Mazloumi Z, et al · · 2026 · PMID 42010708 · DOI 10.1186/s13287-026-05011-7

Verify or expand the search:

Other recruiting trials for Gastric Cancer

Currently open trials in the same condition.

NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting

Other Beijing Doing Biomedical Co., Ltd. trials

Trials by the same sponsor.

NCT02546739 — Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL · Phase 1 · unknown
NCT03271515 — Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL · Phase 1 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02602249 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Doing Biomedical Co., Ltd.
Last refreshed: 1 September 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02602249.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing